Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prednisolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 0.88 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.88 |
| ▸ | PGR | P06401 | 5/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.88 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.88 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.88 |
| ▸ | TNF | P01375 | 1/20 | 0.88 |
| ▸ | IL6 | P05231 | 1/20 | 0.88 |
| ▸ | AR | P10275 | 1/20 | 0.88 |
| ▸ | GLUL | P15104 | 1/20 | 0.88 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.88 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.88 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone SCHEMBL122047 | 1.00 | NR3C1 (0.88) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL7999833 | 0.97 | NR3C1 (0.82) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL8718052 | 0.94 | HIF1A (0.80) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL8432080 | 0.94 | HIF1A (0.80) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL704873 | 0.94 | HIF1A (0.80) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL23863778 | 0.94 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL765329 | 0.94 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL4449434 | 0.94 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL11413677 | 0.94 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL13044469 | 0.94 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113660952-B | Bispecific antibodies | 小野药品工业株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-111670203-B | bispecific antibodies | 小野药品工业株式会社 | 2023-11-14 | — | — | CN | disclosed |
| US-20230041980-A1 | METHOD OF PROTECTING A RESPIRATORY TRACT OR A LUNG FROM DAMAGE, METHOD OF PROTECTING A LUNG FROM PRESSURE DAMAGE INDUCED BY A VENTILATOR, METHOD OF SUPPRESSING SPREAD OF INFECTION WITH VIRUSES OR BACTERIA THAT CAUSE PNEUMONIA IN PULMONARY BRONCHIAL EPITHELIAL CELLS OR ALVEOLAR EPITHELIAL CELLS, AND NASAL SPRAY | NEXT21 KABUSHIKI KAISHA (JP) | 2023-02-09 | — | — | US | disclosed |
| EP-4125927-A1 | MEDICINE CONTAINING TREHALOSE OR TREHALOSE DERIVATIVE AND NASAL SPRAY | Next21 Kabushiki Kaisha (JP) | 2023-02-08 | — | — | EP | disclosed |
| US-20220142915-A1 | Dental Local Anesthetic Solution | SHOWAKAI MEDICAL CO. (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3995132-A1 | DENTAL LOCAL ANESTHETIC SOLUTION | Showakai Medical Co. (JP) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021210648-A1 | MEDICINE CONTAINING TREHALOSE OR TREHALOSE DERIVATIVE AND NASAL SPRAY | NEXT21 KABUSHIKI KAISHA (JP) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021025140-A1 | DUAL-SPECIFIC PROTEIN | 小野薬品工業株式会社 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021020416-A1 | BISPECIFIC ANTIBODY | 小野薬品工業株式会社 | 2021-02-04 | — | — | WO | disclosed |
| WO-2019177117-A1 | DRUG FOR TREATING COUGH | 日本ケミファ株式会社 | 2019-09-19 | — | — | WO | disclosed |
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20060194797-A1 | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-20060135577-A1 | Remedy for chronic disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1661892-A1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-20050187303-A1 | Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1557163-A1 | THERAPEUTIC CAUSING CONTRACTION OF MUCOSAL TISSUE, METHOD OF TREATING DISEASES RELATING TO MUCOSAL TISSUES, INJECTOR AND THERAPEUTIC SET | Japan Science and Technology Agency (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1550461-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1197209-A1 | PERCUTANEOUSLY ABSORBABLE PREPARATIONS | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-0953357-A1 | NEPHROTROPIC DRUGS | Drug Delivery System Institute, Ltd. (JP) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194797-A1 | Condensed ring compound and use thereof | CYSLTR2, CYSLTR1, LTB4R2 | NR3C1 117/4885HIF1A 1982/4885HSD17B10 594/4885 |
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | NR3C1 34/4885HIF1A 340/4885HSD17B10 4005/4885 |
| US-20060135577-A1 | Remedy for chronic disease | EDNRA, EDNRB, LPAR2 | NR3C1 159/4885HIF1A 3307/4885HSD17B10 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.